| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Research Support, Non-U.S. Gov't
- Language: English
- [Neurotherapeutics] 2020 Jan; Vol. 17 (1), pp. 309-328.
- MeSH Terms: Anticonvulsants / *administration & dosage ; Anticonvulsants / *chemistry ; Epilepsy / *drug therapy ; Seizures / *drug therapy ; Animals ; Behavior, Animal / drug effects ; Dose-Response Relationship, Drug ; Epilepsy / chemically induced ; Ethosuximide / chemistry ; Lacosamide / chemistry ; Levetiracetam / chemistry ; Male ; Mice ; Pentylenetetrazole / administration & dosage ; Pyrrolidines / administration & dosage ; Pyrrolidines / chemistry ; Seizures / chemically induced ; Valproic Acid / administration & dosage ; Zebrafish
- References: Nadkarni S, LaJoie J, Devinsky O. Current treatments of epilepsy. Neurology 2005;64:S2–11. (PMID: 10.1212/WNL.64.12_suppl_3.S215994220) ; Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58:522–530. (PMID: 10.1111/epi.136702827606028276060) ; Tang F, Hartz AMS, Bauer B. Drug-resistant epilepsy: multiple hypotheses, few answers. Front Neurol 2017;8:301. (PMID: 10.3389/fneur.2017.00301287298505498483) ; Salpekar JA, Mula M. Common psychiatric comorbidities in epilepsy: How big of a problem is it? Epilepsy Behav doi: https://doi.org/10.1016/j.yebeh.2018.07.023 . ; Thapar A, Kerr M, Harold G. Stress, anxiety, depression, and epilepsy: investigating the relationship between psychological factors and seizures. Epilepsy Behav 2009;14:134–140. (PMID: 10.1016/j.yebeh.2008.09.00418824131) ; Saletti PG, Ali I, Casillas-Espinosa PM, et al. In search of antiepileptogenic treatments for post-traumatic epilepsy. Neurobiol Dis 2019;123:86–9. (PMID: 10.1016/j.nbd.2018.06.01729936231) ; Kaminski RM, Rogawski MA, Klitgaard H. The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics 2014;11:385–400. (PMID: 10.1007/s13311-014-0266-1246718703996125) ; Kamiński K, Rapacz A, Filipek B, et al. Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides. Bioorg Med Chem 2016;24:2938–2946. (PMID: 10.1016/j.bmc.2016.04.06627211245) ; Kamiński K, Zagaja M, Łuszczki JJ, et al. Design, synthesis, and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides. J Med Chem 2015;58:5274–5286. (PMID: 10.1021/acs.jmedchem.5b0057826052884) ; Kamiński K, Rapacz A, Łuszczki JJ, et al. Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives. Bioorg Med Chem 2015;23:2548–2561. (PMID: 10.1016/j.bmc.2015.03.03825868743) ; Abram M, Zagaja M, Mogilski S, et al. Multifunctional Hybrid Compounds Derived from 2-(2,5-Dioxopyrrolidin-1-yl)-3-methoxypropanamides with Anticonvulsant and Antinociceptive Properties. J Med Chem 2017;60:8565–8579. (PMID: 10.1021/acs.jmedchem.7b0111428934547) ; Rapacz A, Kamiński K, Obniska J, et al. Analgesic, antiallodynic, and anticonvulsant activity of novel hybrid molecules derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide in animal models of pain and epilepsy. Naunyn Schmiedebergs Arch Pharmacol 2017;390:567–579. (PMID: 10.1007/s00210-017-1358-3281883575411412) ; Socała K, Mogilski S, Pieróg M, et al. KA-11, a Novel Pyrrolidine-2,5-dione Derived Broad-Spectrum Anticonvulsant: Its Antiepileptogenic, Antinociceptive Properties and in Vitro Characterization. ACS Chem Neurosci 2019;10:636–648. (PMID: 10.1021/acschemneuro.8b0047630247871) ; Rapacz A, Głuch-Lutwin M, Mordyl B, et al. Evaluation of anticonvulsant and analgesic activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides. Epilepsy Res 2018;143:11–19. (PMID: 10.1016/j.eplepsyres.2018.03.02429631129) ; Talevi A. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective. Front Pharmacol 2015;6:205. (PMID: 10.3389/fphar.2015.00205264416614585027) ; Bansal Y, Silakari O. Multifunctional compounds: smart molecules for multifactorial diseases. Eur J Med Chem 2014;76:31–42. (PMID: 10.1016/j.ejmech.2014.01.06024565571) ; Metcalf CS, West PJ, Thomson KE, et al. Development and pharmacologic characterization of the rat 6 Hz model of partial seizures. Epilepsia 2017;58:1073–1084. (PMID: 10.1111/epi.13764284492185469205) ; Wilcox KS, Dixon-Salazar T, Sills GJ, et al. Issues related to development of new antiseizure treatments. Epilepsia 2013;54 (suppl 4):24–34. (PMID: 10.1111/epi.12296239098513947404) ; Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 2004;73:1–60. (PMID: 10.1016/j.pneurobio.2004.03.00915193778) ; Andres-Mach M, Haratym-Maj A, Zagaja M, et al. Additive interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and clobazam in the mouse maximal electroshock-induced tonic seizure model—an isobolographic analysis for parallel dose-response relationship curves. Pharmacology 2014;93:172–177. (PMID: 10.1159/00036064024853974) ; Łuszczki JJ, Zagaja M, Miziak B, et al. Synergistic Interaction of Retigabine with Levetiracetam in the Mouse Maximal Electroshock-Induced Seizure Model: A Type II Isobolographic Analysis. Pharmacology 2015;96:11–15. (PMID: 10.1159/00043082226045245) ; Łuszczki JJ, Zagaja M, Miziak B, et al. Beneficial Combination of Lacosamide with Retigabine in Experimental Animals: An Isobolographic Analysis. Pharmacology 2018;101:22–28. (PMID: 10.1159/00048001928926841) ; Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972;32:281–294. (PMID: 10.1016/0013-4694(72)90177-04110397) ; Leclercq K, Kaminski RM. Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model. Epilepsia 2015;56:310–318. (PMID: 10.1111/epi.1289325524462) ; Litchfield JT, Jr., Wilcoxon F. A simplified method of evaluating dose-effect experiments. 1949;96(2):99–113. ; Łuszczki JJ. Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves. Naunyn Schmiedebergs Arch Pharmacol 2008;378:483–492. (PMID: 10.1007/s00210-008-0305-818566800) ; Andres-Mach M, Zolkowska D, Barcicka-Klosowska B, et al. Effect of ACEA—a selective cannabinoid CB1 receptor agonist on the protective action of different antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:301–309. (PMID: 10.1016/j.pnpbp.2012.07.00122789660) ; Łuszczki JJ, Czuczwar SJ. Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:529–538. (PMID: 10.1016/j.pnpbp.2006.11.02017204358) ; Łuszczki JJ. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn Schmiedebergs Arch Pharmacol 2007;375:105–114. (PMID: 10.1007/s00210-007-0144-z17333129) ; Tallarida RJ. Drug synergism and dose – effect data analysis. Chapman & Hall/CRC, Boca Raton, USA, 2000. (PMID: 10.1201/9781420036107) ; Boissier JR, Tardy J, Diverres JC. Une nouvelle methode simple pour explorer l’action ‘tranquilistante’: le test de la cheminee. Med Exp (Basel) 1960;3:81–84. (PMID: 10.1159/000134913) ; Zagaja M, Andres-Mach M, Patrzylas P, et al. Influence of xanthotoxin (8-methoxypsoralen) on the anticonvulsant activity of various novel antiepileptic drugs against maximal electroshock-induced seizures in mice. Fitoterapia 2016;115:86–91. (PMID: 10.1016/j.fitote.2016.09.0202770266827702668) ; Afrikanova T, Serruys AS, Buenafe OE, et al. Validation of the zebrafish pentylenetetrazol seizure model: locomotor versus electrographic responses to antiepileptic drugs. PLoS One 2013;8:e54166. (PMID: 10.1371/journal.pone.00541662334209723342097) ; Nieoczym D, Socała K, Gaweł K, et al. Anticonvulsant activity of pterostilbene in zebrafish and mouse acute seizure tests. Neurochem Res 2019;44:1043–1055. (PMID: 10.1007/s11064-019-02735-23068916230689162) ; Brown GB. 3H-batrachotoxinin-A benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin. J Neurosci 1986;6:2064–2070. (PMID: 10.1523/JNEUROSCI.06-07-02064.198624264262426426) ; Gould RJ, Murphy KM, Snyder SH. [3H]nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists. Proc Natl Acad Sci U S A 1982;79:3656–3660. (PMID: 10.1073/pnas.79.11.365662853576285357) ; Reynolds IJ, Snowman AM, Snyder SH. (-)-[3H] desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: differentiation by temperature and dihydropyridines. J Pharmacol Exp Ther 1986;237:731–738. (PMID: 3012067) ; Schoemaker H, Langer SZ. [3H]diltiazem binding to calcium channel antagonists recognition sites in rat cerebral cortex. Eur J Pharmacol 1985;111:273–277. (PMID: 10.1016/0014-2999(85)90768-X) ; Wagner JA, Snowman AM, Biswas A, et al. Omega-conotoxin GVIA binding to a high-affinity receptor in brain: characterization, calcium sensitivity, and solubilization. J Neurosci 1988;8:3354–3359. (PMID: 10.1523/JNEUROSCI.08-09-03354.198865694236569423) ; Sills MA, Fagg G, Pozza M, et al. [3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain. Eur J Pharmacol 1991;192:19–24. (PMID: 10.1016/0014-2999(91)90063-V1674916) ; Wang XK. Pharmacological study on recombinant human GABA-A receptor complex containing alpha5 (leucine155 to valine) combined with beta3gamma2s subunits. Acta Pharmacol Sin 2001;22:521–523. (PMID: 11747758) ; Shank RP, Baldy WJ, Mattucci LC, et al. Ion and temperature effects on the binding of gamma-aminobutyrate to its receptors and the high-affinity transport system. J Neurochem 1990;54:2007–2015. (PMID: 10.1111/j.1471-4159.1990.tb04905.x2159983) ; Huang XP, Mangano T, Hufeisen S, et al. Identification of human Ether-a-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. Assay Drug Dev Technol 2010;8:727–742. (PMID: 10.1089/adt.2010.0331211586873002179) ; Phelps PT, Anthes JC, Correll CC. Cloning and functional characterization of dog transient receptor potential vanilloid receptor-1 (TRPV1). Eur J Pharmacol 2005;513:57–66. (PMID: 10.1016/j.ejphar.2005.02.04515878709) ; Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995;48:443–450. (PMID: 7565624) ; Szulczyk B, Nurowska E. Valproic acid inhibits TTX-resistant sodium currents in prefrontal cortex pyramidal neurons. Biochem Biophys Res Commun 2017;491:291–295. (PMID: 10.1016/j.bbrc.2017.07.10928739252) ; Latacz G, Hogendorf AS, Hogendorf A, et al. Search for a 5-CT alternative. In vitro and in vivo evaluation of novel pharmacological tools: 3-(1-alkyl-1H-imidazol-5-yl)-1H-indole-5-carboxamides, low-basicity 5-HT7 receptor agonists. Medchemcomm 2018;9:1882–1890. (PMID: 10.1039/C8MD00313K305687566256855) ; Barton ME, Klein BD, Wolf HH, et al. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001;47:217–227. (PMID: 10.1016/S0920-1211(01)00302-311738929) ; Löscher W. Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans. Eur J Pharmacol 2009;610:1–11. (PMID: 10.1016/j.ejphar.2009.03.02519292981) ; Samokhina E, Samokhin A. Neuropathological profile of the pentylenetetrazol (PTZ) kindling model. Int J Neurosci 2018;128:1086–1096. (PMID: 10.1080/00207454.2018.148106429792126) ; Hansen SL, Sperling BB, Sanchez C. Anticonvulsant and antiepileptogenic effects of GABAA receptor ligands in pentylenetetrazole-kindled mice. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:105–113. (PMID: 10.1016/j.pnpbp.2003.09.02614687864) ; Tokudome K, Okumura T, Shimizu S, et al. Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission. Sci Rep 2016;6:27420. (PMID: 10.1038/srep27420272657814893657) ; Kohling R, Straub H, Speckmann EJ. Differential involvement of L-type calcium channels in epileptogenesis of rat hippocampal slices during ontogenesis. Neurobiol Dis 2000;7:471–482. (PMID: 10.1006/nbdi.2000.030010964616) ; Koshal P, Kumar P. Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice. Mol Cell Biochem 2016;415:77–87. (PMID: 10.1007/s11010-016-2678-126965494) ; Zhu X, Dong J, Han B, et al. Neuronal Nitric Oxide Synthase Contributes to PTZ Kindling-Induced Cognitive Impairment and Depressive-Like Behavior. Front Behav Neurosci 2017;11:203. (PMID: 10.3389/fnbeh.2017.00203290936705651248) ; Azim MS, Agarwal NB, Vohora D. Effects of agomelatine on pentylenetetrazole-induced kindling, kindling-associated oxidative stress, and behavioral despair in mice and modulation of its actions by luzindole and 1-(m-chlorophenyl) piperazine. Epilepsy Behav 2017;72:140–144. (PMID: 10.1016/j.yebeh.2017.03.01928578215) ; Schwabe K, Ebert U. Animal models of epilepsy. In: Animal models of neuropsychiatric diseases. Imperial College Press, 2006, pp. 75–117. ; Łuszczki JJ, Andres-Mach M, Barcicka-Klosowska B, et al. Effects of WIN 55,212-2 mesylate (a synthetic cannabinoid) on the protective action of clonazepam, ethosuximide, phenobarbital and valproate against pentylenetetrazole-induced clonic seizures in mice. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1870–1876. (PMID: 10.1016/j.pnpbp.2011.07.00121777642) ; Löscher W, Hönack D, Fassbender CP, et al. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 1991;8:171–189. (PMID: 10.1016/0920-1211(91)90062-K1907909) ; Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011;52:657–678. (PMID: 10.1111/j.1528-1167.2011.03024.x) ; Whitlow RD, Sacher A, Loo DD, et al. The anticonvulsant valproate increases the turnover rate of gamma-aminobutyric acid transporters. J Biol Chem 2003;278:17716–17726. (PMID: 10.1074/jbc.M20758220012595533) ; Lee WS, Limmroth V, Ayata C, et al. Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 1995;116:1661–1667. (PMID: 10.1111/j.1476-5381.1995.tb16388.x85642341908914) ; Baraban SC. Emerging epilepsy models: insights from mice, flies, worms and fish. Curr Opin Neurol 2007;20:164–168. (PMID: 10.1097/WCO.0b013e328042bae0173514864362672) ; Orellana-Paucar AM, Afrikanova T, Thomas J, et al. Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy. PLoS One 2013;8:e81634. (PMID: 10.1371/journal.pone.0081634243491013862488) ; Copmans D, Rateb M, Tabudravu JN, et al. Zebrafish-Based Discovery of Antiseizure Compounds from the Red Sea: Pseurotin A2 and Azaspirofuran A. ACS Chem Neurosci 2018;9:1652–1662. (PMID: 10.1021/acschemneuro.8b0006029672015) ; Baxendale S, Holdsworth CJ, Meza Santoscoy PL, et al. Identification of compounds with anti-convulsant properties in a zebrafish model of epileptic seizures. Dis Model Mech 2012;5:773–784. (PMID: 10.1242/dmm.010090227304553484860) ; Buenafe OE, Orellana-Paucar A, Maes J, et al. Tanshinone IIA exhibits anticonvulsant activity in zebrafish and mouse seizure models. ACS Chem Neurosci 2013; 4:1479–87. (PMID: 10.1021/cn400140e239370663837379) ; Orellana-Paucar AM, Serruys AS, Afrikanova T, et al. Anticonvulsant activity of bisabolene sesquiterpenoids of Curcuma longa in zebrafish and mouse seizure models. Epilepsy Behav 2012;24:14–22. (PMID: 10.1016/j.yebeh.2012.02.02022483646) ; Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav 2017;70:313–318. (PMID: 10.1016/j.yebeh.2016.11.01628087250) ; Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 2014;5:1131–1141. (PMID: 10.1021/cn500052425029033) ; Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the dravet Syndrome. N Engl J Med 2017;376:2011–2020. (PMID: 10.1056/NEJMoa161161828538134) ; Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA. Preclinical safety and efficacy of cannabidivarin for early life seizures. Neuropharmacology 2019;148:189–198. (PMID: 10.1016/j.neuropharm.2019.01.00230633929) ; Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73:137–150. (PMID: 10.1016/j.eplepsyres.2006.09.00817126531) ; Matsuzawa R, Fujiwara T, Nemoto K, et al. Presynaptic inhibitory actions of pregabalin on excitatory transmission in superficial dorsal horn of mouse spinal cord: further characterization of presynaptic mechanisms. Neurosci Lett 2014;558:186–191. (PMID: 10.1016/j.neulet.2013.11.01724269977) ; Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52:1331–1340. (PMID: 10.1111/j.1528-1167.2011.03109.x2163523621635236) ; Kato AS, Witkin JM. Auxiliary subunits of AMPA receptors: The discovery of a forebrain-selective antagonist, LY3130481/CERC-611. Biochem Pharmacol 2018;147:191–200. (PMID: 10.1016/j.bcp.2017.09.0152898759428987594) ; Witkin JM, Li J, Gilmour G, et al. Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-gamma8-associated AMPA receptors. Neuropharmacology 2017;126:257–270. (PMID: 10.1016/j.neuropharm.2017.07.0282875705028757050) ; Kato AS, Burris KD, Gardinier KM, et al. Forebrain-selective AMPA-receptor antagonism guided by TARP gamma-8 as an antiepileptic mechanism. Nat Med 2016;22:1496–1501. (PMID: 10.1038/nm.42212782060327820603) ; Kerns E, Di L. Drug-like properties—concepts, structure design and methods: from ADME to toxicity optimization. 2nd Edition. Academic Press Cambtidge, 2016.
- Contributed Indexing: Keywords: ADME-Tox properties; Drug-resistant epilepsy; PTZ-kindling model of epilepsy; electrophysiology; isobolographic studies; zebrafish
- Substance Nomenclature: 0 (Anticonvulsants) ; 0 (Pyrrolidines) ; 44YRR34555 (Levetiracetam) ; 563KS2PQY5 (Lacosamide) ; 5SEH9X1D1D (Ethosuximide) ; 614OI1Z5WI (Valproic Acid) ; WM5Z385K7T (Pentylenetetrazole)
- Entry Date(s): Date Created: 20190906 Date Completed: 20210204 Latest Revision: 20240204
- Update Code: 20240205
- PubMed Central ID: PMC7007424
|
